CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's impression of how the review went since the BLA was filed last November, and he discusses what the CRL could mean for the future.
View all episodes
By BiotechTV
5
44 ratings
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's impression of how the review went since the BLA was filed last November, and he discusses what the CRL could mean for the future.
30,635 Listeners
1,867 Listeners
1,087 Listeners
325 Listeners
6,083 Listeners
60 Listeners
9,844 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
499 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners